Search PubMed⌕ Search

Biomedical subjects

L Medleau

Publications and source records attributed to L Medleau.

25 records · Page 2Linked to original sources
PubMed1983

Immunosuppressive effects of cyclophosphamide, vincristine, and L-asparaginase in dogs.

The acute effects of cyclophosphamide, vincristine, and L-asparaginase on the humoral and cell-mediated immune responses in dogs were evaluated. Dogs were given a single dose of cyclophosphamide (10 mg/kg of body weight, IV), a single dose of vincristine (0.025 mg/kg, IV), a single dose of L-asparaginase (400 U/kg, IV), or a combination of these drugs at the aforementioned dosages administered simultaneously. The total number of leukocytes decreased significantly (P = less than 0.05) on posttreatment day 3 in the cyclophosphamide-treated dogs. Antibody responses and lymphocyte blastogenesis were not affected. A transient lymphopenia on posttreatment day 1 was the only response seen in the vincristine-treated dogs. Antibody responses to sheep RBC and lymphocyte blastogenesis were suppressed in the L-asparaginase-treated dogs. L-Asparaginase did not affect the antibody response to bovine serum albumin or peripheral blood leukocyte counts. Suppressed antibody responses to sheep RBC and to bovine serum albumin, depressed lymphocyte blastogenesis, and decreased numbers of all peripheral blood leukocytes were seen in dogs given the 3 drugs in combination.

Animals↗
PubMedDate not supplied

Itraconazole for the treatment of cryptococcosis in cats.

Itraconazole was used in 35 cats with cryptococcosis. Treatment response was determined by comparing clinical signs before, during, and after treatment. It could not be evaluated in 7 cats because they died during treatment from causes unrelated to cryptococcosis. Of the remaining 28 cats, treatment response was classified as success in 16 cats (57%), as improvement in 8 cats (29%), and as a failure in 4 (14%). The failures were due to death or euthanasia from drug toxicity (1 cat), progressive fungal disease (2 cats), and relapse 1 year after treatment (1 cat). The cats that improved did not undergo a 1-year posttreatment evaluation because they were lost to follow-up (3 cats), died or were euthanatized for other reasons (4 cats), or had a noncompliant owner (1 cat). For the 16 cats in which treatment was successful, the median itraconazole dose was 13.8 mg/kg body weight daily (range, 10.9 to 26.7 mg/kg/d), and the median duration of treatment was 8.5 months (range, 4 to 16 months). Five of these cats had previously been treated unsuccessfully with ketoconazole.

Alanine Transaminase↗
PubMedDate not supplied

Cryptococcal infection in cats: factors influencing treatment outcome, and results of sequential serum antigen titers in 35 cats.

The relationship between treatment outcome and location of cryptococcal infection, gender, magnitude of pretreatment cryptococcal antigen titers, results of feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) serology, and serial changes in antigen titers during and after treatment were evaluated in a prospective and nonrandomized study of 35 cats with cryptococcosis. A commercial cryptococcal latex agglutination kit (CALAS; Meridian Diagnostic Inc, Cincinnati, OH) was used to detect cryptococcal antigen in sera. All cats were treated with itraconazole (Sporanox; Janssen Pharmaceutica Inc, Titusville, NJ). Pretreatment mean log titers for serum cryptococcal antigen were not influenced by location of the infection. Treatment outcome was not influenced by gender, location of the infection, or magnitude of pretreatment serum antigen titer. Treatment outcome was influenced by FeLV and FIV status; cats seropositive for FeLV or FIV had a higher likelihood of treatment failure (P = .008). The cryptococcal antigen titers of cats successfully treated decreased with significant linearity over time during treatment (r = -.64, P < .000001), whereas the corresponding titers for cats not treated successfully did not decrease with significant linearity (r = -.03, P > .9). For cats in which treatment was successful, antigen titers decreased significantly from pretreatment values by 1.3 orders of magnitude at 2 months after initiation of treatment. By 10 months after initiating treatment, log titers decreased by at least 2 orders of magnitude in all cats successfully treated, and 9 of 16 cats had undetectable titers. In contrast, in 5 of 6 cats in which treatment failed, antigen titers were unchanged or increased in magnitude even after at least 6 months of treatment.

Agglutination Tests↗
PubMedDate not supplied

Thyroid-stimulating hormone stimulation tests in cardiomyopathic Doberman pinschers: a retrospective study.

Thyroid-stimulating hormone (TSH) response tests were performed in 152 Doberman Pinschers. Seventy-nine dogs had cardiomyopathy (46 were in congestive heart failure [CHF] and 33 were not in CHF). Seventy-three dogs were presented for noncardiac problems (15 with skin disease, 21 with neurologic disease, 20 with internal medicine disorders, and 17 with other problems), although some may have had cardiomyopathy. The TSH response test results in the cardiomyopathic group were interpreted as normal or euthyroid-sick in 45 (57%) dogs, abnormal in 23 (29%) dogs, and equivocal in 11 (14%) dogs. The prevalence of hypothyroidism in the CHF and non-CHF cardiomyopathy groups was not different. Among the dogs presented for noncardiac problems, 27 (37%) were assessed as normal or euthyroid-sick, 29 (40%) as hypothyroid, and 17 (23%) as equivocal. No significant differences were found in the prevalence of hypothyroid test results among the subgroups of these dogs. The prevalence of hypothyroidism was not higher in the cardiomyopathic group compared to the other group, and 63 and 49% of cardiomyopathic dogs with or without CHF, respectively, tested as either euthyroid or euthyroid-sick.

Animals↗
PubMedDate not supplied

Efficacy of daily amitraz therapy for refractory, generalized demodicosis in dogs: two independent studies.

In two independent studies, 0.125% amitraz solution applied half-body daily was found 73% effective in curing dogs with demodicosis previously refractory to biweekly or weekly amitraz treatments. Thirteen of the 16 cases that resolved did so after one course of treatment which ranged from four weeks to five months in duration. The other three cases initially relapsed but then were cured after they were re-treated. All cases deemed cured, including those that initially relapsed, were followed for at least one year after their last treatment.

Administration, Topical↗
PubMedDate not supplied

Evaluation of topical therapies for the treatment of dermatophyte-infected hairs from dogs and cats.

Seven commonly used, topical antifungal products (i.e., lime sulfur, chlorhexidine, captan, povidone-iodine, sodium hypochlorite, and enilconazole solutions, and ketoconazole shampoo) were evaluated for their antifungal activity on Microsporum canis-infected hairs from dogs and cats in an in vitro study. Hairs were soaked or shampooed in each product for five minutes twice a week for four weeks. Of the seven products used in this study, lime sulfur and enilconazole solutions were superior in inhibiting fungal growth; no growth occurred on fungal cultures after two treatments with either product. Chlorhexidine and povidone iodine solutions were effective after four treatments, and sodium hypochlorite solution and ketoconazole shampoo inhibited fungal growth after eight treatments. Captan did not inhibit fungal growth during the test period.

Administration, Topical↗